Elevated serum transforming growth factor β1 levels in Epstein-Barr virus-associated diseases and their correlation with virus-specific immunoglobulin A (IgA) and IgM

Journal of Virology

Volumn 74, Issue 5, 2000, Pages 2443-2446

  Xu, Jingwu ^a   Ahmad, Ali ^a   Jones, James F ^b   Dolcetti, Riccardo ^c   Vaccher, Emanuela ^c   Prasad, Umapati ^d   Menezes, José ^a  

^a UNIVERSITY OF MONTREAL   (Canada)

^b NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^c CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^d UNIVERSITY OF MALAYA   (Malaysia)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN A; IMMUNOGLOBULIN M; TRANSFORMING GROWTH FACTOR BETA1;

ANTIBODY TITER; ARTICLE; BLOOD LEVEL; BURKITT LYMPHOMA; EPSTEIN BARR VIRUS; HUMAN; IMMUNOPATHOGENESIS; INFECTIOUS MONONUCLEOSIS; MAJOR CLINICAL STUDY; NASOPHARYNX CARCINOMA; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL;

ANTIBODIES, VIRAL; EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN M; REGRESSION ANALYSIS; TRANSFORMING GROWTH FACTOR BETA;

EID: 0033951067     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.74.5.2443-2446.2000     Document Type: Article

References (27)

1. Ahmad, A., and J. Menezes. 1997. Binding of the Epstein-Barr virus to human platelets causes the release of transforming growth factor-β1. J. Immunol. 159:3984-3988.
2. Blomhoff, H. K., E. Smeland, A. S. Mustafa, T. Godal, and R. Ohlsson. 1987. Epstein-Barr virus mediates a switch in responsiveness to transforming growth factor, type beta, in cells of the B cell lineage. Eur. J. Immunol. 17:299-301.
3. Border, W. A., and N. A. Noble. 1995. Targeting TGF-β for treatment of disease. Nature Med. 1:1000-1001.
4. Cayrol, C., and E. K. Flemington. 1995. Identification of cellular target genes of the Epstein-Barr virus transactivator Zta: activation of transforming growth factor beta igh3 (TGF-β igh3) and TGF-β1. J. Virol. 69:4206-4212.
5. Epstein, M. A., A. J. Morgan, S. Finerty, B. J. Randle, and J. K. Kirkwood. 1985. Protection of cottontop tamarins against Epstein-Barr virus-induced malignant lymphoma by a prototype subunit vaccine. Nature 318:287-289.
6. Ivanovic, V., A. Melman, B. Davis-Joseph, M. Valcic, and J. Geliebter. 1995. Elevated plasma levels of TGF-β1 in patients with invasive prostate cancer. Nature Med. 1:282-284.
7. Kadin, M. F., M. W. Cavaille-Coll, R. Gertz, J. Massagué, S. Cheifetz, and D. George. 1994. Loss of receptors for transforming growth factor β in human T-cell malignancies. Proc. Natl. Acad. Sci. USA 91:6002-6006.
8. Kagnoff, M. F. 1996. Mucosal immunology: new frontiers. Immunol. Today 17:57-61.
9. Khanna, R., S. R. Burrows, and D. J. Moss. 1995. Immune regulation in Epstein-Barr virus-associated diseases. Microbiol. Rev. 59:387-405.
10. Kong, L. M., M. S. Anscher, T. Muraset, D. A. Abbott, J. D. Iglehart, and R. L. Jirtle. 1995. Elevated plasma transforming growth factor-β1 levels in breast cancer patients decrease after surgical removal of the tumor. Ann. Surg. 222:155-162.
11. Letterio, J. J., and A. B. Roberts. 1998. Regulation of immune responses by TGF-β. Annu. Rev. Immunol. 16:137-161.
12. Markowitz, S., J. Wang, and L. Myeroff. 1995. Inactivation of the type II TGF-β receptor in colon cancer cells with microsatellite instability. Science 268:1336-1338.
13. Massagué, J. 1992. Receptors for the TGF-β family. Cell 69:1067-1070.
14. Moore, K. W., A. O'Gara, R. deWaal-Malefyt, P. Vierra, and T. R. Mossmann. 1993. Interleukin 10. Annu. Rev. Immunol. 11:165-190.
15. Morgan, A. J. 1992. Epstein-Barr virus vaccines. Vaccine 10:563-571.
16. Nomori, H., T. Kameya, Y. Shimosato, H. Saito, S. Ebihara, and I. Ono. 1985. Nasopharyngeal carcinoma: immunohistochemical study for keratin, secretory component and leukocyte common antigen. Jpn. J. Clin. Oncol. 15:95-105.
17. Okano, M., G. M. Thiele, J. R. Davis, H. L. Grierson, and D. T. Purtilo. 1988. Epstein-Barr virus and human diseases: recent advances in diagnosis. Clin. Microbiol. Rev. 1:300-312.
18. Pi, G. H., Y. Zeng, and H. Wolf. 1987. Detection of IgA antibody to EBV membrane antigen using staphylococcus aureus preabsorbed sera is closely associated with nasopharyngeal carcinoma. J. Virol. Methods 15: 33-39.
19. Renzo, L. D., A. Altoik, G. Klein, and E. Klein. 1994. Endogenous TGF-β contributes to the induction of the EBV lytic cycle in Burkitt lymphoma cell lines. Int. J. Cancer 57:914-919.
20. Rickinson, A. B., and E. Kieff. 1996. Epstein-Barr virus, p. 2397-2446. In B. N. Fields, D. M. Knipe, and P. M. Howley (ed.), Fields virology, 3rd ed. Lippincott-Raven Publishers, Philadelphia, Pa.
21. Shirai, Y., S. Kawata, S. Tamura, N. Ito, H. Tsushima, and K. Takaishi. 1994. Plasma transforming growth factor-β1 in patients with hepatocellular carcinoma: comparison with chronic liver diseases. Cancer 73:2275-2279.
22. Sixbey, J. W., and Q. Y. Yao. 1992. Immunoglobulin A-induced shift of Epstein-Barr virus tissue tropism. Science 255:1578-1580.
23. Stavnezer, J. 1995. Regulation of antibody production and class switching by TGF-β. J. Immunol. 155:1647-1651.
24. Xu, J. W., A. Ahmad, M. Blagdon, M. D'Addario, J. F. Jones, R. Dolcetti, E. Vaccher, U. Prasad, and J. Menezes. 1998. The Epstein-Barr virus (EBV) major envelope glycoprotein gp350/220-specific antibody reactivities in the sera of patients with different EBV-associated diseases. Int. J. Cancer 79: 481-486.
25. Xu, J. W., J. Menezes, U. Prasad, and A. Ahmad. 1999. Elevated serum levels of transforming growth factor β1 in Epstein-Barr virus-associated nasopharyngeal carcinoma patients. Int. J. Cancer 84:396-399.
26. Yao, Q. Y., M. Rowe, A. J. Morgan, C. K. Sam, U. Prasad, H. Dang, Y. Zeng, and A. B. Rickinson. 1991. Salivary and serum IgA antibodies to the Epstein-Barr virus glycoprotein gp340: incidence and potential for virus neutralization. Int. J. Cancer 48:45-50.
27. Zhang, Y., T. Musci, and R. Derynck. 1997. The tumor suppressor Smad4/DPC4 as a central mediator of Smad function. Curr. Biol. 7:270-276.